

## Nova Eye Medical Limited completes Retail Entitlement Offer

### Highlights

- Total capital raise of \$8.0 million, before costs, now completed
- Fully underwritten Retail Entitlement Offer raises approximately \$2.9 million
- Valid applications under the Top-Up Facility to be honoured in full
- New shares under the Retail Entitlement Offer issued 15 March 2024, will trade on 18 March 2024

**Nova Eye Medical Limited** (ASX: EYE) (**Nova Eye Medical** or the **Company**), a medical technology company committed to advanced ophthalmic treatment technologies and devices, today announces the completion of the fully underwritten Retail Entitlement Offer (**Retail Entitlement Offer**) which was announced on 12 February 2024 and closed on 8 March 2024.

Valid applications from eligible retail shareholders for 5,448,301 shares were received and accepted. Eligible retail shareholders who applied for shares under the top-up facility can expect to receive the full quantum of their valid applications. An additional total of 8,286,811 shares have been allocated to the underwriters in accordance with the terms of the underwriting agreement.

Shares issued through the Retail Entitlement Offer (**New Shares**) will rank *pari passu* to existing shares on issue. New Shares will be issued on Friday, 15 March 2024, and commence trading on Monday, 18 March 2024.

The Retail Entitlement Offer raised approximately \$2.9 million and completes the capital raising undertaken to advance near-term growth opportunities across Nova Eye Medical's Glaucoma business, including expanding the geographical presence of *iTrack™ Advance* sales in the US and Europe, and to broaden the product portfolio in Glaucoma surgical devices.

The institutional component of the capital raising, that settled on 21 February 2024, raised a total of approximately \$5.1 million through a private placement and accelerated non-renounceable entitlement offer. Approximately 24.3 million shares were allocated to existing and new institutional and sophisticated investors. Both the retail and institutional components were priced at \$0.21 per share.

E&P Corporate Advisory acted as sole Bookrunner to the transaction. E&P Corporate Advisory, MST Financial Services and Taylor Collison acted as Joint Lead Managers.

**Authorised for lodgement by the Board of Directors of Nova Eye Medical Limited.**

**– ENDS –**

**Company**

Tom Spurling  
Managing Director  
+61 417 818 658  
[tspurling@nova-eye.com](mailto:tspurling@nova-eye.com)

**Company**

Kate Hunt  
Chief Commercial Officer  
+61 404 080 679  
[khunt@nova-eye.com](mailto:khunt@nova-eye.com)

**Investors**

Mark Flynn  
Investor Relations  
+61 416 068 733  
[mflynn@nova-eye.com](mailto:mflynn@nova-eye.com)

---

**ABOUT NOVA EYE MEDICAL**

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye’s natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit:  
[www.nova-eye.com](http://www.nova-eye.com)